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As patients advance through the model, their BMD progresses and they are at risk
of fracture (hip, vertebral, other) and of death. BMD changes, fracture risks and
mortality were all based on the Dubbo Osteoporosis Epidemiology Study (DOES).
Utility values were based on the patients fracture status. Evidence for the efficacy
of alendronate in the prevention of fracture was the clinical fracture arm of the
Fracture Intervention Trial (FIT). RESULTS: The incremental cost per QALY of
broadening access to alendronate compared with current practice was $34,808
(incremental costs of $783 per patient with 0.0225 QALYs gained). Broadening ac-
cess to alendronate resulted in fewer fracture-related deaths (301 per 100,000 pop-
ulation), hip fractures (904), vertebral fractures (259) and other fractures (1098).
CONCLUSIONS: Broadening primary prevention treatment of osteoporotic fracture
with alendronate to individuals aged 70 years with BMD T–scores  – 2.5 will
prevent fractures and save lives at good value-for-money.
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OBJECTIVES: Increasing real-life adherence to bisphosphonates therapy is impor-
tant to achieve the clinical benefits of reducing fractures reported in randomized
clinical trials (RCTs). The aim of this pharmacoeconomic analysis was to determine
the cost-effectiveness of a pharmaceutical care intervention program in commu-
nity pharmacies, aimed to increase bisphosphonates adherence for the prevention
of osteoporotic fractures. METHODS: A decision analytical model was constructed
with a time horizon of three years, discounting at 4.0% and 1.5% annually for costs
and effects, respectively. A Dutch healthcare provider’s perspective was adopted.
Adherence and efficacy data were gathered from a Dutch pharmaceutical care
program in community pharmacies (the MeMO intervention). The association be-
tween bisphosphonate adherence and osteoporotic fractures was modelled using
Dutch clinical studies. Recent and upcoming reimbursement policy changes in The
Netherlands were modelled with a scenario of therapeutic substitution, character-
ized by drastically lower drug prices. RESULTS: Adherence to bisphosphonates
therapy in The Netherlands was 68.3%. The pharmaceutical care intervention pro-
gram increased bisphosphonates adherence to 83.9% (P0.001). If the intervention
program would be introduced nationwide in community pharmacies, 337 osteopo-
rotic fractures would be prevented and 47 quality-adjusted life years (QALYs)
would be gained. Additional medication and intervention costs were €1,738,000;
the cost-savings due to reduced fractures were €998,000. The cost-effectiveness of
the pharmaceutical care intervention was €16,000 per QALY. When drug prices
decline following therapeutic substitution policies, the intervention will be
cost-saving. CONCLUSIONS: Pharmaceutical care programs in community phar-
macies, such as the MeMO intervention, can improve bisphosphonate adherence,
resulting in a considerable number of osteoporotic fractures being prevented.
Therapeutic substitution policies that lower drug prices will increase the cost-
effectiveness of interventions that increase adherence. This study demonstrates
the value of pharmaceutical care programs in community pharmacies to increase
therapy adherence.
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OBJECTIVES: Dupuytren’s contracture (DC) is a progressive disorder that limits
hand function and impacts on patient’s ability to work or to perform their daily
activities. Current standard of care is limited fasciectomy, a surgical procedure that
removes part of the affected cord. Collagenase clostridium histolyticum (CCH) is the
first licensed pharmacological treatment for DC patients with a palpable cord. This
study aims to estimate costs of CCH versus fasciectomy in Portuguese DC patients.
METHODS: A cost minimization approach was adopted, with effectiveness as-
sumed to be equivalent for CCH and fasciectomy. Resource use was elicited
through a panel of five Portuguese experts with extensive clinical experience. Fa-
sciectomy’ direct costs of included surgery in-patient cost and post-surgery costs:
follow up outpatient visits and physiotherapy. CCH’ direct costs included vials
costs, administration of injection in an outpatient setting and a follow up outpa-
tient visit. Fasciectomy induced indirect costs were estimated by the human cap-
ital method. Unit costs were extracted from Portuguese literature and official
sources. Societal perspective was adopted. RESULTS: Average direct cost per pa-
tient for CCH and fasciectomy were respectively 2,099€ and 2,366€. Average saving
per patient is 267€, a reduction of 11% direct fasciectomy costs. Although inclusion
of indirect costs can introduce some uncertainty due to measurement error, they
should be analysed given their relevance to the society: average saving per patient
estimate is 1,407€ when we include productivity costs. CONCLUSIONS: CCH is a
convenient, minimally invasive, effective and generally well tolerated alternative
to surgery for DC’ patients. Adoption of CCH as an alternative to fasciectomy offers
a choice for DC’ patients, and provides an efficient approach to the treatment of DC
by reducing the demand for physiotherapy and in-patient services. On average,
CCH is cost saving in Portugal compared with fasciectomy and induces superior
savings when indirect costs are included.
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OBJECTIVES: Denosumab has been shown to be a cost-effective use of NHS re-
sources for the treatment of postmenopausal osteoporosis in England and Wales.
This study assessed the cost-effectiveness of denosumab given Scottish treatment
and resource use patterns. METHODS: A probabilistic model employed in a recent
submission to NICE was used with resource use amended to reflect local expert
advice. This indicated zoledronate requires an annual pre-infusion assessment
appointment and that patients failing on, or unable to take oral bisphosphonates
are referred to secondary care for advice on further treatment. Denosumab is mod-
elled as initiated in secondary care, with subsequent injections in primary care.
Fracture risk for 70 year old women with bone mineral density T-score 2.5 was
based on a published algorithm and accounted for prior fracture. Relative efficacy
of osteoporosis therapies was based on meta-analysis and adjusted indirect com-
parison. Utilities reflected patients’ age and modelled health states. All therapies’
administration was costed using NHS Reference and PSSRU costs. Drug costs were
from the British National Formulary. Costs and utilities were discounted at 3.5%.
RESULTS: Denosumab dominated strontium ranelate and IV ibandronate in both
cohorts, and was cost-effective versus raloxifene (£4,339/QALY without prior frac-
ture and dominant in patients with prior fracture). Denosumab was also cost-
effective against no treatment: cost/QALY £22,380 and £9,618 in patients without
and with prior fracture respectively. IV zoledronate and denosumab each produced
very similar QALYs in the two cohorts, however, denosumab’s costs were approx-
imately £1,000 lower in each. Zoledronate’s cost/QALY ratios against denosumab
were £120,000 and £50,000, i.e. zoledronate was not cost-effective against deno-
sumab. Denosumab had the greater probabilities of being cost-effective at thresh-
old values of £30,000/QALY in both cohorts. CONCLUSIONS: Denosumab was
shown to be cost-effective against all comparators in both primary and secondary
care settings. Compared with zoledronate, denosumab may be a better use of NHS
resources.
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OBJECTIVES: To evaluate the cost-utility and budget impact (BI) of certolizumab
pegol (CZP) as an add-on therapy to methotrexate (MTX) versus other first line
biological DMARDs, in the treatment of adult patients with active RA who did not
respond adequately to DMARDs, including MTX, in Greece. METHODS: A Markov
(cohort health state transition) model was developed to evaluate the cost-utility of
CZP versus other TNF- inhibitors recommended in Greece (etanercept [ETA], ada-
limumab [ADA] and infliximab [IFX]). Treatment efficacy was measured using the
ACR-responses (ACR20/50/70) at 6 months. ACR estimated rates were based on
adjusted indirect comparison (MTX as common comparator) of published clinical
trials. Utilities were derived from EQ-5D data from CZP RA clinical trials. Clinical
history/resource use data came from published literature. Sensitivity analyses
were conducted. The BI of CZP as an add-on therapy to MTX was estimated from
payer perspective over 2011–2015. The alternatives to CZP include all TNF- inhib-
itors recommended in Greece (etanercept, adalimumab, infliximab, golimumab).
Epidemiological data were used to estimate the RA population eligible for CZP
therapy. Published 2011 hospital unit costs (drug acquisition, administration, mon-
itoring, resources) in both analyses were taken from Greek routine sources/expert
opinion. Base case analysis assumed a payer perspective, costs discounted at 3.5%
(CU/BI), a lifetime horizon, with outcomes discounted at 3.5% (CU), 75kg patient-
fixed average weight (BI). RESULTS: Base case analysis indicated that CZP is cost-
effective compared with all combination therapies considered (at €60,000(3xGDP/
capita) willingness-to-pay threshold), with an incremental cost-effectiveness ratio
of €19,181/QALYs, €32,208/QALYs, €22,349/QALYs versus ADAMTX, ETAMTX
and IFXMTX, respectively. In terms of BI, the introduction of CZP on the Greek
market produced cumulative net savings of €7.68M during 2011–2015.
CONCLUSIONS: This analysis shows that CZPMTX is cost-effective versus. the
other TNF- inhibitors recommended in Greece for the treatment of RA and its use
is anticipated to result in budgetary net savings.
PMS46
COST-UTILITY ANALYSIS OF CERTOLIZUMAB PEGOL VERSUS ALTERNATIVE
TUMOR NECROSIS FACTOR-INHIBITORS, FOR THE TREATMENT OF MODERATE-
TO-SEVERE RHEUMATOID ARTHRITIS IN SPAIN
Villoro R1, Hidalgo A2, Ferro B3, Talavera P3
1Instituto Max Weber, Madrid, Spain, 2Castilla-La Mancha University, Toledo, Spain, 3UCB
Pharma S.A., Madrid, Spain
OBJECTIVES: To evaluate the cost-utility of CZP compared with standard-of-care
first-line administered TNF-inhibitors  MTX in the treatment of moderate-to-
severe RA in Spain.METHODS:A Markov (cohort health state transition) model was
developed to evaluate the cost-utility of CZP versus the other TNF-inhibitors li-
censed and recommended in Spain (etanercept [ETA], adalimumab [ADA], and
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infliximab [IFX]). Treatment efficacy was measured using ACR-responses (ACR20,
ACR50 or ACR70) at 6 months. ACR estimated response rates were based on ad-
justed indirect comparison (MTX as the common comparator) of published clinical
trials. Utilities were derived from EQ-5D data collected in CZP RA clinical trials.
Clinical history and resource use data came from published literature. Unit costs
(drug, administration, monitoring, and resources) were taken from Spanish routine
sources or published references (cost year 2009). Base case analysis was conducted
from the payer perspective, with a lifetime horizon, annual discounting rates of
costs and outcomes of 3.5% and inflation rate for 2009 onwards of 3%. One-way
sensitivity analyses were conducted. RESULTS: The average lifetime costs for
CZPMTX, ETAMTX, ADAMTX and IFXMTX were €140,971, €141,197, €139,148
and €136,961, respectively. The quality-adjusted life-years (QALYs) gained were
6.578, 6.462, 6.430 and 6.318, respectively. The deterministic cost-effectiveness
analysis found that CZPMTX dominated ETAMTX (lower cost, greater QALYs),
and that CZPMTX was cost-effective vs ADAMTX and IFXMTX at the €30,000/
QALY willingness-to-pay threshold (ICERs of €12,346/QALY and €15,414/QALY, re-
spectively). One-way sensitivity analyses showed that ICERs were most sensitive to
the change in annual discount rates, the model cycle (evaluation of ACR response
at 3 instead of 6 months), the analysis perspective and the estimation of utilities
(HAQ-DI mapping instead of direct evaluation from EQ-5D). CONCLUSIONS: This
analysis shows that CZPMTX is cost-effective versus the other considered TNF-
inhibitors recommended in Spain for the treatment of RA.
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OBJECTIVES: To evaluate the cost-effectiveness of golimumab (Gol) treatment in
severe, active Ankylosing Spondylitis (AS). METHODS: A Markov model was con-
structed based upon the literature, to model the progression of a cohort of AS
patients treated with Gol and its comparators over a 20 year time frame. The
comparators considered were adalimumab (Ada) and etanercept (Eta) and all were
compared to standard care which was comprised of a combination of nonsteroidal
anti-inflammatory drugs (NSAIDs), disease modifying antirheumatic drugs
(DMARDs), Cox-2 inhibitors and physiotherapy. Long-term efficacy was based on
regressions estimated from the Gol phase III trial (GO RAISE) and the literature.
Short-term comparative efficacy was derived from a mixed treatment comparison.
The outcome measure was quality-adjusted life-years (QALYs). Utilities were esti-
mated through use of an algorithm translating BASFI and BASDAI progression to
EQ-5D. Costs were based on the literature (long-term) and expert opinion (short-
term). Uncertainty was explored through deterministic and probabilistic sensitiv-
ity analysis (PSA). RESULTS: Compared to conventional therapy, the incremental
cost-effectiveness ratios (ICERs) of the biologic TNF- inhibitors Gol, Ada and Eta
were £30,043, £30,187 and £30,810 respectively, with the TNF- inhibitors having
similar QALYs and costs. In the sensitivity analysis, time horizon and baseline
BASFI and BASDAI scores had the biggest impact on the results. Gol was seen to
provide the greatest net monetary benefit (NMB) of all the TNF- inhibitors at all
willingness to pay (WTP) thresholds up to £30,000 per QALY. CONCLUSIONS: Gol is
a highly effective and well-tolerated therapy for the treatment of patients with
severe, active AS and represents a treatment option with similar cost-effectiveness
versus conventional care as the TNF- inhibitors currently approved by the Na-
tional Institute for Health and Clinical Excellence (NICE) in the UK.
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OBJECTIVES: To estimate the cost-utility of denosumab compared with generic
alendronate, generic risedronate, oral ibandronate, strontium ranelate and no
treatment to prevent osteoporotic fractures in Spanish postmenopausal women.
METHODS: A validated Markov cohort model was adapted to the Spanish osteopo-
rotic patient population (women aged 65 years, T-score2.5 SD and a prevalence
of morphometric vertebral fractures of 36%) to represent the possibility of transi-
tioning through different health states: well, hip fracture, vertebral fracture, wrist
fracture, other osteoporotic fractures, post-vertebral fracture, post hip fracture and
death. Efficacy data on fracture risk reduction were derived from a phase III trial for
denosumab versus placebo and a meta-analysis conducted by NICE for compara-
tors with follow-up of one to three years. The perspective of the Spanish National
Healthcare System was used and costs were referred to 2010. The model included
treatment persistence during the intended 5-year treatment period and assumed a
two year linear decline in efficacy after discontinuation. Persistence data for all
treatments were obtained from prescription data and a persistence study. Results
were presented in incremental cost-effectiveness ratios (ICERs). RESULTS: The
base-case ICERs were estimated at €17,345, €25,397, and €14,543 per QALY for de-
nosumab compared with no treatment, generic alendronate, and generic risedro-
nate. Denosumab was dominant against oral ibandronate and strontium ranelate
since resulted in lower costs and better efficacy. CONCLUSIONS: This analysis
showed that denosumab is a cost-effective treatment option compared to oral
osteoporosis treatments.
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OBJECTIVES: Rituximab (MabThera™) selectively targets B cells and represents an
effective therapeutic approach for RA in addition to existing treatments, such as
disease-modifying anti-rheumatic drugs (DMARDs) and tumour necrosis factor
(TNF) inhibitors. This study explores the cost-effectiveness of rituximab in TNF-IR
patients in the The Netherlands. METHODS: The analysis reflects efficacy of the
compared strategies based on two parameters: ACR response and HAQ score. A
network meta-analysis provided evidence on the comparative efficacy of treat-
ments based on ACR response. Evidence from the REFLEX trial and secondary
sources are used to project HAQ score changes of patients over time. Cost input for
the analysis is derived from local sources in the The Netherlands. Utility data
(EQ-5D) from a patient registry is analysed and categorised into six HAQ score
bands based on disease severity. All input is synthesised through an individual
simulation model that compares three treatment strategies after failure of a first
TNF: one sequence containing rituximab, one containing TNF (i.e. TNF-cycling) and
one containing abatecept. Uncertainty around model parameters is explored
through probabilistic sensitivity analysis. A scenario analysis uses data on loss of
productivity to estimate the indirect costs of the comparing strategies.RESULTS: In
the base-case analysis, the strategy with rituximab dominates the other strategies.
The result is the same in probabilistic sensitivity analysis where over 98% of the
samples show that the sequence with rituximab dominates both other strategies.
CONCLUSIONS:The addition of rituximabMTX in the standard of care of patients
with inadequate response to TNF treatment is estimated to be a cost-effective
strategy.
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OBJECTIVES: We developed a cost-effectiveness model of biological therapy (BT)
compared with methotrexate (MTX) alone, using a combination of information
from 150 patients at Hospital Militar in Bogota, Colombia, and from international
trials and economic aggregated data. METHODS: We designed a Markov model
with five functional states, based on Health Assessment Questionnaire (HAQ). Five
simulations were estimated through hypothetical cohorts of patients, with similar
characteristics to our observed sample, who initiated treatment in each of the five
states defined for the disease. Simulations were run for 10 and 20 years under
different scenarios. Utilities, in QALY were taken from Tufts CEA Registry. Discount
rates: 6% for costs and 1.5% for utilities. We calculated both direct and indirect
costs, converted into US dollars. RESULTS: In the ten-year base case, incremental
cost effectiveness ratios (ICER) (in US$ per additional QALY gained) for each of the
five functional states in increasing severity order, were $153,184; $139,466;
$130,281; $134,752 and $109,934,respectively. In the twenty-year base case, ICERs
were $119,025; $112,921; $108,124; $110,520 and $98,119, respectively. Total costs
were lower with MTX, despite higher indirect costs and complication costs. How-
ever, BT treatment represented more QALYs regardless of the initial state. More-
over, it is more cost-effective to start the treatment from advanced disease states.
BT would not be cost-effective in Colombia when using WHO cost-effectiveness
threshold (3 times per capita GDP of US$6200) and even less so using other thresh-
olds (US$ 50,000; €50,000 or £30,000 per QALY gained). CONCLUSIONS: BT com-
pared to MTX provides more QALYs to the patients, but at a high cost. When ICERs
were estimated for Colombia, BT would not be cost effective under usual thresh-
olds. A serious dilemma arises. We suggest establishing different thresholds for
different conditions, giving priority to chronic diseases that can lead to serious
disability.
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OBJECTIVES: There are 5 anti-TNF agents licensed for the treatment of RA in Ire-
land; adalimumab, certolizumab pegol, etanercept, golimumab and infliximab. Re-
imbursement agencies have issued mixed approvals for their use through either a
multiple assessment process or a single technology appraisal process. Significant
uncertainties have been identified through these assessments. A multiple treat-
ment comparison of these agents, focusing on the uncertainties previously high-
lighted, in the Irish health care setting is the focus of this study. METHODS: The
Birmingham Rheumatoid Arthritis Model 2009 was used to estimate the cost effec-
tiveness of anti-TNF agents in patients with established RA who were non-re-
sponders to methotrexate. The perspective taken is that of the Irish Healthcare
Payer. Evidence synthesis of HAQ data (via a multiplier), long and short term sur-
vival data was performed in WinBUGs and used to inform the effect parameter in
the model. Irish cost data was applied. Utility mapping between HAQ, EQ-5D (re-
vised scoring) and SF-6D was used to model utility gain. Probabilistic analysis was
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